Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by research analysts at Citigroup to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.
Several other brokerages have also issued reports on GLX. Citizens Jmp raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, December 9th. ATB Cormark Capital Markets cut Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research note on Thursday, February 5th. Five analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Bradmer Pharmaceuticals presently has an average rating of “Buy”.
Check Out Our Latest Analysis on GLX
Bradmer Pharmaceuticals Price Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon
- Gilder: Don’t Buy AI Stocks, Do This Instead
- Read this or regret it forever
- What Expenses Can Be Deducted From Capital Gains Tax This Year?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
